Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC |
Harris MelodyPresident, Enterprise Ops
|
GrantStock Option (Right to Buy) · Derivative | 42,344 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000027 · wk-form4_1709069261.xml · derivative · entry 6 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 42,344 shares Expires 2034-02-23 F6 · derivative.exercise_date: On February 23, 2024, Ms. Harris was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantPerformance Stock Unit · Derivative | 25,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 8 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,330 Underlying: Common Stock · 25,330 shares Expires not disclosed F10 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantRestricted Stock Unit · Derivative | 25,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 7 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,329 Underlying: Common Stock · 25,329 shares Expires not disclosed F9 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantStock Option (Right to Buy) · Derivative | 42,344 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 6 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 42,344 shares Expires 2034-02-23 F8 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:32 UTC |
Olivo Alicia CGeneral Counsel
|
SaleCommon Stock | 2,587 | $14.96 | $38,712.90 |
DisclosureSEC source: 0001077183-24-000013 · wk-form4_1708464760.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,866 F1 · balance_after: This balance includes 313 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:28 UTC |
Harris MelodyPresident, Enterprise Ops
|
Tax withholdingCommon Stock | 7,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000002 · wk-form4_1704320872.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,955 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the January 1, 2024 vesting of restricted stock. F2 · balance_after: This balance includes 514 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| December 07, 2023 Filed Dec 12, 2023 00:54 UTC |
Sherman Jeffrey ScottChief Financial Officer
|
Tax withholdingCommon Stock | 8,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000144 · wk-form4_1702342485.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,662 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the December 7, 2023 vesting of restricted stock. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:49 UTC |
Stone WarrenPresident, Clinical Services
|
Tax withholdingCommon Stock | 5,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000142 · wk-form4_1701812953.xml · nonDerivative · entry 1 Stone Warren · CIK 0001955295 · President, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,775 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2023 vesting of restricted stock. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 21:33 UTC |
Olivo Alicia CGeneral Counsel
|
SaleCommon Stock | 2,669 | $18.39 | $49,082.91 |
DisclosureSEC source: 0001077183-23-000140 · wk-form4_1700516026.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,140 F1 · balance_after: This balance includes 311 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 21:50 UTC |
Olivo Alicia CGeneral Counsel
|
Tax withholdingCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000127 · wk-form4_1696369845.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,498 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the September 30, 2023 vesting of restricted stock. F2 · balance_after: This balance includes 101 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 21:27 UTC |
Olivo Alicia CGeneral Counsel
|
Tax withholdingCommon Stock | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000125 · wk-form4_1693949212.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,411 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the September 1, 2023 vesting of restricted stock. F2 · balance_after: This balance includes 96 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC |
Perez David BrianDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000123 · wk-form4_1692049358.xml · derivative · entry 4 Perez David Brian · CIK 0001765355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC |
Perez David BrianDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000123 · wk-form4_1692049358.xml · derivative · entry 3 Perez David Brian · CIK 0001765355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC |
Zook Anthony P.Director
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000122 · wk-form4_1692049312.xml · derivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC |
Zook Anthony P.Director
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000122 · wk-form4_1692049312.xml · derivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:41 UTC |
HANNAH ALISON L.Director
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000121 · wk-form4_1692049280.xml · derivative · entry 8 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:41 UTC |
HANNAH ALISON L.Director
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000121 · wk-form4_1692049280.xml · derivative · entry 7 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:40 UTC |
Kelly Michael AaronDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000120 · wk-form4_1692049223.xml · derivative · entry 6 Kelly Michael Aaron · CIK 0001769668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:40 UTC |
Kelly Michael AaronDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000120 · wk-form4_1692049223.xml · derivative · entry 5 Kelly Michael Aaron · CIK 0001769668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:39 UTC |
KANOVSKY STEPHEN MDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000119 · wk-form4_1692049173.xml · derivative · entry 7 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:39 UTC |
KANOVSKY STEPHEN MDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000119 · wk-form4_1692049173.xml · derivative · entry 6 KANOVSKY STEPHEN M · CIK 0001713090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:38 UTC |
CROWTHER BRUCE KDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000117 · wk-form4_1692049088.xml · derivative · entry 5 CROWTHER BRUCE K · CIK 0001244274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:38 UTC |
CROWTHER BRUCE KDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000117 · wk-form4_1692049088.xml · derivative · entry 4 CROWTHER BRUCE K · CIK 0001244274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:36 UTC |
Floegel ElizabethDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000115 · wk-form4_1692048986.xml · derivative · entry 2 Floegel Elizabeth · CIK 0001984128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:36 UTC |
Floegel ElizabethDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000115 · wk-form4_1692048986.xml · derivative · entry 1 Floegel Elizabeth · CIK 0001984128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:37 UTC |
TETRAULT LYNN A.Director
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000116 · wk-form4_1692049037.xml · derivative · entry 8 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:37 UTC |
TETRAULT LYNN A.Director
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000116 · wk-form4_1692049037.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:35 UTC |
Gunn NeilDirector
|
GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000114 · wk-form4_1692048920.xml · derivative · entry 2 Gunn Neil · CIK 0001984436 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:35 UTC |
Gunn NeilDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000114 · wk-form4_1692048920.xml · derivative · entry 1 Gunn Neil · CIK 0001984436 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| August 01, 2023 Filed Aug 1, 2023 21:26 UTC |
Olivo Alicia CGeneral Counsel
|
Tax withholdingCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000092 · wk-form4_1690925171.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,981 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2023 vesting of restricted stock. F2 · balance_after: This balance includes 301 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:01 UTC |
Sikri VishalPresident Advanced Diagnostics
|
Tax withholdingCommon Stock | 21,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001931406-23-000002 · wk-form4_1685743307.xml · nonDerivative · entry 1 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,716 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the June 1, 2023 vesting of restricted stock. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:29 UTC |
TETRAULT LYNN A.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001077183-23-000064 · wf-form4_168496374962456.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,507 shares Expires 2023-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:29 UTC |
TETRAULT LYNN A.Director
|
Exercise / conversionCommon Stock | 1,507 | $11.60 | $17,481.20 |
DisclosureSEC source: 0001077183-23-000064 · wf-form4_168496374962456.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC |
Smith Christopher MChief Executive Officer
|
GrantPerformance Stock Unit · Derivative | 144,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 5 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,190 Underlying: Common Stock · 144,190 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC |
Smith Christopher MChief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 144,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 4 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,190 Underlying: Common Stock · 144,190 shares Expires not disclosed F3 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC |
Smith Christopher MChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 269,841 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,841 Underlying: Common Stock · 269,841 shares Expires 2030-05-11 F2 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Sherman Jeffrey ScottChief Financial Officer
|
GrantPerformance Stock Unit · Derivative | 39,016 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 5 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Underlying: Common Stock · 39,016 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Sherman Jeffrey ScottChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 39,016 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Underlying: Common Stock · 39,016 shares Expires not disclosed F3 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Sherman Jeffrey ScottChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 73,016 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,016 Underlying: Common Stock · 73,016 shares Expires 2030-05-11 F2 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 73,016 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Stone WarrenPresident, Clinical Services
|
GrantPerformance Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000052 · wf-form4_168418475762442.xml · derivative · entry 5 Stone Warren · CIK 0001955295 · President, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Stone WarrenPresident, Clinical Services
|
GrantRestricted Stock Unit · Derivative | 28,838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000052 · wf-form4_168418475762442.xml · derivative · entry 4 Stone Warren · CIK 0001955295 · President, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,838 Underlying: Common Stock · 28,838 shares Expires not disclosed F3 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:06 UTC |
Stone WarrenPresident, Clinical Services
|
GrantStock Option (Right to Buy) · Derivative | 53,969 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000052 · wf-form4_168418475762442.xml · derivative · entry 3 Stone Warren · CIK 0001955295 · President, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,969 Underlying: Common Stock · 53,969 shares Expires 2030-05-11 F2 · derivative.exercise_date: On May 11, 2023, Mr. Stone was granted 53,969 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantPerformance Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 5 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F7 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantRestricted Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 4 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Sikri VishalPresident Advanced Diagnostics
|
GrantStock Option (Right to Buy) · Derivative | 39,683 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 3 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,683 Underlying: Common Stock · 39,683 shares Expires 2030-05-11 F4 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Harris MelodyPresident, Enterprise Ops
|
GrantPerformance Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 5 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F6 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Harris MelodyPresident, Enterprise Ops
|
GrantRestricted Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 4 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F4 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Harris MelodyPresident, Enterprise Ops
|
GrantStock Option (Right to Buy) · Derivative | 39,683 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 3 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,683 Underlying: Common Stock · 39,683 shares Expires 2030-05-11 F3 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Olivo Alicia CGeneral Counsel
|
GrantPerformance Stock Unit · Derivative | 19,508 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000049 · wf-form4_168418469409508.xml · derivative · entry 10 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,508 Underlying: Common Stock · 19,508 shares Expires not disclosed F10 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F9 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC |
Olivo Alicia CGeneral Counsel
|
GrantRestricted Stock Unit · Derivative | 19,508 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000049 · wf-form4_168418469409508.xml · derivative · entry 9 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,508 Underlying: Common Stock · 19,508 shares Expires not disclosed F8 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F9 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.